![Madrigal Pharmaceuticals](https://s33007.pcdn.co/wp-content/uploads/2020/11/Madrigal-Pharmaceuticals-Inc.jpg)
Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver.